Welcome to our new international investors that have extensive experience in leveraging platform technologies to develop multi-product opportunities.
Ruth Devenyns - CEO
PRECIRIX® (previously called Camel-IDS), was founded in 2014 as a spin-off from Vrije Universiteit Brussel (VUB). Precirix is a clinical-stage biotechnology company dedicated to improving the lives of cancer patients by developing novel targeted radiopharmaceuticals using camelid single domain antibody fragments. The company is advancing its lead product CAM-H2 through a Phase I/II clinical trial targeting HER2-positive tumors, while further progressing and broadening its oncology pipeline. Precirix’ technology platform allows for a theranostic approach, using the same molecule for patient selection (imaging) and therapy (or fast and specific delivery of therapeutic radiation to cancer cells, while sparing healthy tissues).
When ambition meets ambition
The PRECIRIX® team has a renowned expertise in radio-immunotherapy and is well positioned to move up to the next level.
This investment clearly fits into our Health & Care strategy and, with a platform portfolio of about 20 companies, underpins our position as one of the most active European investors in the healthcare industry.
Together, we build a leading company
With this financing, which is one of the larger rounds of a European early-stage life sciences company, PRECIRIX® will be able to run a phase Ib/II trial with its lead program targeting brain metastatic breast cancer, while further progressing and broadening its preclinical pipeline. We are delighted that we can contribute to this lead program thanks to our expertise through earlier investments in life sciences companies.